Renalytix Plc (AIM:RENX)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX 5.35
-0.20 (-3.59%)
Nov 6, 2026, 4:20 PM GMT
Renalytix Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 3 | 3 | 2.3 | 3.4 | 2.97 | |
Revenue Growth | 0% | 30.44% | -32.41% | 14.58% | 99.19% |
Cost of Revenue | 1.8 | 1.8 | 2.1 | 2.68 | 2.1 |
Gross Profit | 1.2 | 1.2 | 0.2 | 0.72 | 0.87 |
Selling, General & Admin | 13.9 | 17.3 | 23.4 | 28.66 | 39.52 |
Research & Development | 1.1 | 0.9 | 5.1 | 14.3 | 14.65 |
Operating Expenses | 15.1 | 18.2 | 30.5 | 42.96 | 54.17 |
Operating Income | -13.9 | -17 | -30.3 | -42.24 | -53.3 |
Interest Expense | -0.7 | -0.5 | - | - | - |
Interest & Investment Income | - | - | 0.2 | 0.1 | 0.01 |
Earnings From Equity Investments | - | - | - | -0.01 | 0.01 |
Currency Exchange Gain (Loss) | - | 0.3 | -0.5 | 0.36 | 9.69 |
Other Non Operating Income (Expenses) | - | -0.1 | - | 0.36 | 0.12 |
EBT Excluding Unusual Items | -14.6 | -17.3 | -30.6 | -41.44 | -43.46 |
Gain (Loss) on Sale of Investments | -0.1 | -0.6 | -0.6 | -1.08 | -5.9 |
Asset Writedown | - | - | -10.5 | - | - |
Other Unusual Items | - | -3.9 | -3.8 | -3.09 | 4.11 |
Pretax Income | -14.7 | -21.8 | -45.5 | -45.61 | -45.25 |
Income Tax Expense | -0.5 | -1.4 | - | 0 | 0.03 |
Earnings From Continuing Operations | -14.2 | -20.4 | -45.5 | -45.61 | -45.28 |
Net Income | -14.2 | -20.4 | -45.5 | -45.61 | -45.28 |
Net Income to Common | -14.2 | -20.4 | -45.5 | -45.61 | -45.28 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 410 | 275 | 108 | 82 | 73 |
Shares Outstanding (Diluted) | 410 | 275 | 108 | 82 | 74 |
Shares Change | 49.15% | 153.82% | 31.59% | 11.34% | 3.29% |
EPS (Basic) | -0.03 | -0.07 | -0.42 | -0.55 | -0.62 |
EPS (Diluted) | -0.03 | -0.07 | -0.42 | -0.55 | -0.67 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -11 | -17.9 | -29.8 | -34.09 | -46.48 |
Free Cash Flow Per Share | -0.03 | -0.07 | -0.28 | -0.41 | -0.63 |
Gross Margin | 40.00% | 40.00% | 8.70% | 21.16% | 29.43% |
Operating Margin | -463.33% | -566.67% | -1317.39% | -1241.26% | -1794.55% |
Profit Margin | -473.33% | -680.00% | -1978.26% | -1340.20% | -1524.44% |
Free Cash Flow Margin | -366.67% | -596.67% | -1295.65% | -1001.62% | -1565.02% |
EBITDA | -13.7 | -16.8 | -30.1 | -41.93 | -53.01 |
D&A For EBITDA | 0.2 | 0.2 | 0.2 | 0.31 | 0.29 |
EBIT | -13.9 | -17 | -30.3 | -42.24 | -53.3 |